Incidence of Atrial Fibrillation in Patients With Severe Obstructive Sleep Apnea: The Reveal XT-SA Study
Launched by DR. ADRIAN BARANCHUK · Jan 27, 2010
Trial Information
Current as of August 19, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients with severe OSA defined as Apnea Hypopnea Index (AHI) \> 30.
- • 2. Age \> 18 years.
- Exclusion Criteria:
- • 1. Previous history of clinical AF defined as documented lone, paroxysmal, persistent or permanent, according to standard definitions.
- • 2. Patient with anticipated requirement of MRI.
- • 3. Patient with well-know allergy to any component of the Medtronic Reveal XT.
- • 4. Patients with implantable cardiac rhythm device \[pacemakers or internal cardiac device (ICDs)\].
- • 5. Women of child bearing potential.
- • 6. Unable or unwilling to provide written informed consent.
- • 7. Unable or unwilling to complete the study follow-up schedule (eg. intention to leave the Kingston area over the next 3 years.
- • 8. Previously enrolled in this trial.
- • 9. Enrolled in another study that would confound the results of this trial.
- • 10. Documented history of heart failure
- • 11. Diagnosed with severe obstructive sleep apnea greater than 1 year from screening date
About Dr. Adrian Baranchuk
Dr. Adrian Baranchuk is a distinguished clinical researcher and cardiologist renowned for his contributions to the field of electrophysiology and heart rhythm disorders. As a clinical trial sponsor, he leads innovative research initiatives aimed at advancing medical knowledge and improving patient outcomes in cardiovascular health. Dr. Baranchuk's expertise encompasses the design and execution of trials that explore novel therapeutic approaches and technologies, fostering collaboration among multidisciplinary teams. His commitment to ethical research practices and patient safety ensures that all clinical trials under his sponsorship adhere to the highest standards of scientific rigor and integrity.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kingston, Ontario, Canada
Patients applied
Trial Officials
Adrian Baranchuk, MD
Principal Investigator
Queen's University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials